Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.52 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.52 |
| ▸ | TYMP | P19971 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338677 | 0.89 | POLB (0.57) | POLBENPP1P2RY1ABCB1GSK3A | |
| SCHEMBL532525 | 0.89 | P2RX3 (0.55) | POLBENPP1P2RY1ABCB1GSK3A | |
| SCHEMBL532524 | 0.89 | P2RX3 (0.55) | POLBENPP1P2RY1ABCB1GSK3A | |
| SCHEMBL8714855 | 0.88 | ENPP1 (0.57) | POLBENPP1P2RY1ABCB1GSK3A | |
| SCHEMBL159558 | 0.87 | POLB (0.56) | POLBENPP1P2RY1ABCB1GSK3A | |
| SCHEMBL4466114 | 0.87 | ABCB1 (0.60) | POLBENPP1P2RY1ABCB1GSK3A | |
| SCHEMBL2027173 | 0.86 | POLB (0.58) | POLBENPP1P2RY1GSK3ARPS6KA3 | |
| SCHEMBL7519500 | 0.86 | PNP (0.50) | POLBENPP1P2RY1ABCB1TYMP | |
| SCHEMBL7519498 | 0.86 | PNP (0.50) | POLBENPP1P2RY1ABCB1TYMP | |
| SCHEMBL9650579 | 0.86 | P2RY12 (0.50) | POLBP2RY1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0754242-A4 | OLIGONUCLEOTIDE N3'-m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS INC (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | claimed |
| EP-0548189-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE. | STERLING WINTHROP INC (US) | 1993-06-30 | — | — | EP | claimed |
| WO-1992004364-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE | STERLING WINTHROP INC. (US) | 1992-03-19 | — | — | WO | claimed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20260028368-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | INTEGRATED DNA TECH INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12459968-B2 | Oligonucleotide synthesis on solid support | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12006540-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999999-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-04 | — | — | US | disclosed |
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-16 | — | — | US | disclosed |
| CN-112533892-B | Alkoxyphenyl derivative, nucleoside protector, nucleotide protector, method for producing oligonucleotide, and method for removing substituent | 藤本化学制品株式会社 | 2023-09-08 | — | — | CN | disclosed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| EP-0548189-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE. | STERLING WINTHROP INC (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992004364-A1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE | STERLING WINTHROP INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0202758-A1 | Hybridization method and probes therefor | ZENECA LIMITED (GB) | 1986-11-26 | — | — | EP | disclosed |
| EP-0058954-A2 | Tridecadeoxynucleotide, process for its preparation and the application | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | POLB 10/4885ENPP1 1463/4885P2RY1 4622/4885 |
| US-20260028368-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | NSUN2, RNGTT, POLR2H | POLB 15/4885ENPP1 1608/4885P2RY1 3707/4885 |
| US-11999999-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | POLB 10/4885ENPP1 1463/4885P2RY1 4622/4885 |
| US-12006540-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | POLB 10/4885ENPP1 1463/4885P2RY1 4622/4885 |
| US-12459968-B2 | Oligonucleotide synthesis on solid support | RNGTT, SSU72, NSUN2 | POLB 26/4885ENPP1 1218/4885P2RY1 4592/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | POLB 25/4885ENPP1 969/4885P2RY1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.